A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Omilancor (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms BT-11-202
- Sponsors Landos Biopharma; NImmune Biopharma
Most Recent Events
- 11 Apr 2025 According to NImmune Biopharma media release, company will present results from this trial at Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.
- 06 Jun 2023 Status changed from suspended to discontinued as per the dcision of Landos Biopharma (not related to safety or efficacy).
- 31 Mar 2022 This trial has been discontinued in Austria and Slovakia (End Date: 10 Feb 2022), according to European Clinical Trials Database record.